ReviewFrontiers in immunology2026
Exposure-shaped immunometabolic networks in chronic liver disease: translating multi-omics and artificial intelligence into preventive biomarkers.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic liver disease develops through sustained interactions among metabolic stress, environmental exposure, immune activation, and tissue remodeling. These processes are often studied as separate domains, yet in patients they converge within the same hepatic microenvironment and help explain why disease trajectories vary even within the same diagnostic category. Exposure science has sharpened attention to diet, alcohol, pollutants, chemical mixtures, gut-derived signals, sleep and circadian disruption, and other behavioral determinants of liver injury. At the same time, multi-omics approaches now capture complementary dimensions of disease biology, including genetic susceptibility, epigenetic memory, inflammatory transcriptional programs, proteomic signaling, metabolic rewiring, microbiome composition, and spatially restricted cell states. The central challenge is no longer simply to generate more data, but to connect these layers into clinically useful markers of progression. In this review, we discuss chronic liver disease as a set of exposure-shaped immunometabolic network states that extend across steatosis, inflammation, fibrosis, cirrhosis, and hepatocellular transformation. We summarize how major exposure domains feed into shared pathogenic hubs, how immune and metabolic circuits sustain injury, and how genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiome profiling, and single-cell or spatial methods can reveal biologically coherent biomarker candidates. We also examine how machine learning, deep learning, network-based modeling, and causal-inference strategies may support risk stratification and progression forecasting when used with attention to interpretability, cohort structure, and external validation. A prevention-oriented biomarker framework should identify transition-prone states early enough to guide monitoring, referral, treatment selection, or lifestyle intervention. Such translation will require better exposure assessment, longitudinal sampling, assay standardization, and transportable models tested across real-world populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.